Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

Inclusion Criteria: * Histologically confirmed primary glioblastoma multiforme (GBM) * Patient must have previously undergone standard chemoradiation- 59.4 Gy (1.8 Gy/fraction) or 60 Gy (2.0 Gy/fraction) with concurrent and adjuvant Temodar (temozolomide) * Patient must be diagnosed with recurrent GBM either with biopsy or radiographically * Karnofsky Performance Status (KPS) \>= 70 * Ability to understand and willingness to sign a written informed consent * If a woman is of childbearing potential, a negative serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study treatment and for up to 4 weeks following the study treatment * For the purpose of this study, all women are considered to be of childbearing potential unless they are post-menopausal at least 1 year since last menses), biologically sterile, or surgically sterile (i.e. hysterectomy, bilateral oophorectomy or tubal ligation) Exclusion Criteria: * Patients with active infection * Patients with KPS \< 70 and/or unable to tolerate potentially longer treatment times * Refusal to sign informed consent * Pregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study treatment * Note: Concurrent and/or adjuvant chemotherapy does not make a patient ineligible; participation in a concurrent treatment protocol does not make a patient ineligible